CPRX vs DBVT vs ALKS vs IQV

For growth investors, Catalyst Pharmaceuticals, Inc.

(CPRX) is the stronger pick with 19. 8% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Catalyst Pharmaceuticals, Inc. (CPRX) offers the better valuation at 18. 6x trailing P/E (16. 6x forward), making it the more compelling value choice. Analysts rate Catalyst Pharmaceuticals, Inc. (CPRX) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Catalyst Pharmaceuticals, Inc.

(CPRX) is the cheapest at 18. 6x versus Alkermes plc at 24. 8x. On forward P/E, IQVIA Holdings Inc. is actually cheaper at 14. 1x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: IQVIA Holdings Inc. wins at 0. 35x versus Catalyst Pharmaceuticals, Inc. 's 0. 88x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Catalyst Pharmaceuticals, Inc.

(CPRX) delivered a total return of +545. 2%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: CPRX returned +48. 0% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Catalyst Pharmaceuticals, Inc.

(CPRX) is the lower-risk stock at 0. 88β versus IQVIA Holdings Inc. 's 1. 33β — meaning IQV is approximately 51% more volatile than CPRX relative to the S&P 500. On balance sheet safety, Catalyst Pharmaceuticals, Inc. (CPRX) carries a lower debt/equity ratio of 0% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Catalyst Pharmaceuticals, Inc.

(CPRX) is pulling ahead at 19. 8% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Catalyst Pharmaceuticals, Inc. grew EPS 28. 2% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, CPRX leads at 40. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Catalyst Pharmaceuticals, Inc.

(CPRX) is the more profitable company, earning 36. 4% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 36. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CPRX leads at 43. 8% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, IQVIA Holdings Inc. (IQV) is the more undervalued stock at a PEG of 0. 35x versus Catalyst Pharmaceuticals, Inc. 's 0. 88x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, IQVIA Holdings Inc. (IQV) trades at 14. 1x forward P/E versus 16. 6x for Catalyst Pharmaceuticals, Inc. — 2. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Catalyst Pharmaceuticals, Inc.

(CPRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 88)). Both have compounded well over 10 years (CPRX: +48. 0%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CPRX is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock; ALKS is a small-cap quality compounder stock; IQV is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.